Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

VerifyNow French Registry (VERIFRENCHY)

This study has been completed.
Boston Scientific Corporation
Cordis Corporation
Information provided by (Responsible Party):
RANGE Gregoire, Association Pour le Développement des Soins Cardiologiques de la ville de Chartres Identifier:
First received: September 15, 2008
Last updated: June 24, 2015
Last verified: June 2015

The purpose of this study is to determine the effect of clopidogrel or aspirin reactivity as measured by a point-of-care platelet function assay on thrombotic or bleeding events after percutaneous coronary intervention (PCI) with drug eluting or bare metal stent.


Platelet reactivity on clopidogrel and aspirin therapy is measured before PCI with VerifyNow (Accumetrics Inc.,San Diego, CA, USA) P2Y12 or aspirin assay respectively in 1000 consecutive patients from 20 centers in France undergoing coronary angioplasty with stent.

Exclusion criteria are:

Acute myocardial infarction, treatment with vitamin K antagonists and the use of antiGP2b3a before PCI. All patients are pre-treated with clopidogrel and aspirin. Non-response to aspirin or clopidogrel is determined according to the result of the VerifyNow assay (cut off : < 15 % for P2Y12 and > 550 ARU for aspirin). The primary end point is the occurrence of definite or probable stent thrombosis (ARC definition) and the secondary end-points include global and cardio-vascular mortality, non fatal myocardial infarction and major bleeding. A clinical evaluation is scheduled at discharge and by telephone contact at one month and one year.

Stent Thrombosis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation of the Occurence of Thrombotic and Bleeding Events After Coronary Angioplasty With Stent According to Aspirin and Clopidogrel Platelet Reactivity Assessed by a Point of Care Assay in the Cathlab (the Verifynow French Registry)

Resource links provided by NLM:

Further study details as provided by Association Pour le Développement des Soins Cardiologiques de la ville de Chartres:

Primary Outcome Measures:
  • Stent thrombosis [ Time Frame: one year ]

Secondary Outcome Measures:
  • Mortality, cardio-vascular mortality, non fatal Myocardial infarction, urgent coronary revascularisation , re-hospitalization, severe bleeding [ Time Frame: one year ]

Enrollment: 1001
Study Start Date: February 2008
Study Completion Date: November 2009
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
real world patient referred for coronary angioplasty with stent

Inclusion Criteria:

  • Coronary angioplasty with stent

Exclusion Criteria:

  • Use of AGP2b3a
  • Acute myocardial infarction
  • No aspirin and clopidogrel pretreatment
  • Use of AVK
  • Aspirin or clopidogrel contre-indication
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00753753

cardiology unit / Les hopitaux de Chartres
Chartres, Eure Et Loir, France, 28000
Sponsors and Collaborators
Association Pour le Développement des Soins Cardiologiques de la ville de Chartres
Boston Scientific Corporation
Cordis Corporation
Principal Investigator: gregoire rangé GACI
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: RANGE Gregoire, MD, Association Pour le Développement des Soins Cardiologiques de la ville de Chartres Identifier: NCT00753753     History of Changes
Other Study ID Numbers: VERIfynow FRENCH registrY
CPP n°2008-N2
AFFSAPS 2008-A00411-54
Study First Received: September 15, 2008
Last Updated: June 24, 2015

Keywords provided by Association Pour le Développement des Soins Cardiologiques de la ville de Chartres:
stent thrombosis

Additional relevant MeSH terms:
Pathologic Processes
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents processed this record on April 28, 2017